DOCKET NO.: BMS-0307

PATENT

In the Claims:

Please cancel Claims 113, 115, 122, 124, 229 to 238, 245 to 248, 255 to 270, 277 to 280, 287 to 292, and 357 to 411, without prejudice.

Please amend Claims 100, 127, and 351 to read as follows:

100. (Twice amended) A formulation for therapeutic or diagnostic use comprising targeted lipid vesicles having encapsulated therein a gas selected from the group consisting of perfluorocarbons and sulfur hexafluoride, said targeted lipid vesicles comprising a conjugate that comprises a lipid, a linking group, and a targeting ligand, wherein said linking group is a hydrophilic polymer that is covalently bound to both said lipid and said targeting ligand, and is selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, polyvinylalcohol, polyvinylpyrrolidone, and copolymers thereof, and wherein said targeting ligand targets cells or receptors selected from the group consisting of myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPHbHHa receptor.

£5/

bioactive agent comprising administering to a patient a therapeutically effective amount of a formulation which comprises, in combination with a bioactive agent, targeted lipid vesicles having encapsulated therein a gas selected from the group consisting of perfluorocarbons and sulfur hexafluoride, said targeted lipid vesicles comprising a conjugate that comprises a lipid, a linking group, and a targeting ligand, wherein said linking group is a hydrophilic polymer that is covalently bound to said lipid and said targeting ligand, and is selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, polyvinylalcohol, polyvinylpyrrolidone, and copolymers thereof, and wherein said targeting ligand targets cells or receptors selected from the group consisting of myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor.